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We investigated gender­dependent differences of genistein (isoflavone phytoestrogen) 
treatment in a penicillin­induced experimental epilepsy rat model. Twenty­eight adult Wistar 
Albino rats (14 females and 14 males) were devided into four groups, control and genistein­
treatmed males and females. Genistein (100 µg/kg, i.p) or saline was given during 15 days 
before the electrocorticography (ECoG) recordings. The epileptiform activity was induced 
by penicillin G potassium solt (500 IU, i.c) injections into the left somatomotor cortex. 
Significant differences among the groups were found in the latency to onset of epileptiform 
activity. This value in the female control group was significantly longer than the latencies in 
the male control, male genistein, and female genistein groups (respectively, P = 0.002, 0.015, 
and 0.032). There were no significant differences regarding the spike/wave frequencies and 
amplitudes in epileptiform activity between female/male genistein and control groups within 
all observation intervals (P > 0.05). Thus, genistein exerts a proconvulsant effect in the 
penicillin­induced epilepsy model, and the effect demonstrates the clear gender specificity 
related to the specificity of hormonal backgrounds in males and females. 
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INTRODUCTION
Epilepsy is one of the most common neurological 
diseases with a high incidence in the world.  The disease 
is based on changes in the neuronal excitation/inhibition 
balance. It is usually characterized by the occurence 
of prolonged recurrent and unprovoked seizures [1]; 
this is mostly related abnormal hypersynchronous 
electrical activity of cerebral cortical neurons [2]. 
The development and manifestations of epileptiform 
activity are, to a significant extent, based on alteration 
of GABAergic transmission; it should be taken into 
account that GABAergic transmission could be 
responsible for both seizure­suppressing and seizure­
promoting actions [3]. Despite extensive research 
of epilepsy and the respective seizure mechanisms, 
successful mechanism­based treatment approaches 
have not been developed until now. Many researchers 
examine and try to understand the pathogenesis of 
epilepsy using different experimental epilepsy models, 
including the penicillin­induced epilepsy model [4, 5].
The mentioned disease is more complicated in 
women compared to that in men; there are some 
interactions between epileptic manifestations and the 
level of female hormones [6, 7]. There are indication 
that sex gonadal hormones of both females and males 
exert significant effects on the neuronal excitability 
and seizure suspectibility in epilepsy. Thus, effects 
of gender specificity should be taken into account 
in different experimental epilepsy models [7–9]. In 
this context, some clinical and experimental studies 
have been declared that estrogen hormones provide 
proconvulsant effects, while progesterone exerts 
an anticonvulsant effect on epileptic seizures [8–
10]. However, the data on the effects of estrogens 
on epileptiform activity are controversial [9–13]. 
Results of both clinical and experimental studies 
indicated that estrogens are mostly proconvulsant 
effects [9–11], while others reports emphasized the 
predominance of anticonvulsant effects [12, 13]. 
Opposite effects of estrogens may depend on many 
factors, such as a hormone type, differences between 
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natural or synthetic hormone preparations, regional 
distiribution of hormone receptors, treatment duration, 
estrogen dose, hormonal status, regions of the nervous 
or neurotransmitter systems involved, seizure type in 
the model used, and sex [7, 13]. 
Phytoestrogens are rather similar in their effects to 
animal estrogen; they can directly bind to estrogen 
receptors (ERs) mainly ERb . These compounds 
mimic estrogen functions in particular modulation of 
gene expression. Isoflavone phytoestrogens can act 
as agonists or antagonists of ERs. These substances 
manifest estrogenic and/or anti­estrogenic properties 
owing to phenolic rings in the chemical structure of 
their molecules. Genistein (4’, 5,7­trihidroksiflovan) 
is an isoflavone phytoestrogen; its main source are 
soybeans. Isoflavones, particularly genistein and 
daidzein, have agonist, with respect to estrogen, 
effects; they selectively bind to ERs and mimick 
some effects of estrogen [14]. Thus, these agents 
were proposed to be used as an alternative to natural 
compounds in estrogen replacement theraphy (ERT). 
It was also shown that genistein exerts inhibitory 
effects on protein tyrosine kinase (PTK), which plays 
an important role in intracellular signal pathways, 
via modulation of the functions of ion channels [15, 
16]. Additionally, genistein was reported to exert a 
negative regulatory effect on GABA activity [17].  
The aim of our study was to investigate the effects 
of genistein with special attention to gender­dependent 
differences in the action of this phytoestrogen, 
observed in a penicillin­induced experimental epilepsy 
model in rats. 
METHODS
Animals. Experiments were performed on 28 adult 
Wistar albino rats (14 females and 14 males) weighing 
300­350 g. Animals were housed three to four per cage 
under a 12 h light/dark cycle at room temperature of 
22­25°C and 40­50% humidity, with free access to 
water. The rats were kept at 80­85% of their free­
feeding body mass during the experiment.  
Chemicals and Experimental Groups. Genistein 
(> 97%) was purchased from Sigma Aldrich (USA) and 
dissolved in dimethyl sulfoxide (DMSO). Booth ge-
nistein and saline (control) were given i.p. during a 
15­day­long treatment period in the genistein and sa-
line groups, respectively. The epileptiform activity was 
induced by 2.5 µl intracortical penicillin G potassium 
injection (500 IU, Sigma Chemical, USA) to all rats.  
In our study, a relatively low dose (100 µg/kg, i.p.) 
genistein not showing any cytotoxic and apoptotic 
effects was used, as previously reported [18]. Animals 
were divided into two main groups, male and female 
ones (M and F). Each gender group was additionally 
divided into two groups, control and genistein treated 
(C and G). Thus, animals were randomly divided into 
the following four equal groups (n = 7 in each), MC, 
MG, FC, and FG. 
Electrocorticography. All rats were anesthetized 
with 1.2 g/kg urethane (Sigma Aldrich, USA, i.p) and 
placed in a stereotaxic apparatus (Harvard Apparatus, 
USA) before surgical operation. After controlling the 
anesthesia depth, eye and claw reflexes were checked. 
An incision (length 2­4 cm) was made on the skull 
in the rostro­caudal direction. The left cerebral cortex 
was exposed by craniotomy (2 mm posterior to the 
bregma and 3 mm lateral to the sagittal line); bone 
particles and dura mater were carefully removed. 
Two Ag/AgCl ball electrodes were placed over the 
left somatomotor cortex (first electrode, 2 mm lateral 
to the sagittal suture and 1 mm anterior to bregma, 
second electrode, 2 mm lateral to the suture and 5 
mm posterior to the bregma). The common reference 
electrode was fixed on the left pinna. 
The ECoG activity was continuously monitored on a 
recorder (PowerLab 8/SP, AD Instruments, Australia); 
ECoG signals were amplified and filtered (0.1­50 Hz 
bandpass) using BioAmp amplifiers (AD Instruments, 
Australia) and digitized at a sampling rate 1024 sec–1 
using a four­channel data acquisition system (PowerLab 
8/SP, AD Instruments, Australia). The baseline activity 
in each group was recorded within the first 5 min. 
After observation of basal activity within the 
above interval, epileptiform activity was induced 
by intracortical (i.c) injection of 2.5 µl penicillin G 
potassium salt dissolved in sterile physiological saline 
into the left sensorimotor cortex (2 mm posterior to 
the bregma, 3 mm lateral to the sagittal suture, and 
2 mm ventral to the brain surface) using a Hamilton 
microinjector at the infusion rate 0.5 µl/min in all 
rats. The ECoG activity was continuously recorded 
during 180 min, displayed, digitized, and stored for 
post­experimental computer analysis. The frequency 
(min–1) and amplitude (µV) values of the spike/wave 
complexes and the latency (sec) of onset of the first 
spike/wave event in each animal were automatically 
measured using a data acquisition Chart v. 6.0 system 
(Power Lab software; AD Instruments, Pty Ltd., 
Australia) and analyzed offline. 
Statistical Analysis. The epileptiform activity was 
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analyzed after numerical conversion within every 
10­min­long interval during 180 min recording. The 
above­mentioned ECoG parameters were gathered from 
all groups, and these values were analyzed using PASW 
package (ver. 18). Descriptive values were computed 
as means ± s. d. and medians. The Kruskal­Wallis test 
was used for comparing each group with respect to the 
spike­wave latency, frequency, and amplitude within 
each period. In addition, the post­hoc Dunn’s test 
followed the Kruskal­Wallis test were used. Bonferroni­
corrected P values were used for comparing these 
indices among different groups. The P < 0.05 values 
were considered to be statistically significant.
RESULTS
Effects of Genistein on Penicillin G-Induced 
Epileptiform Activity. The epileptiform activity 
characterized by spikes and spike­wave complexes 
started 2­5 min after penicillin injection, reached 
constant levels of the frequency and amplitude in 30 
min, and lasted for 3­5 h (Fig. 1). Data comprising 
the mean spike/wave frequency and amplitude values 
and latencies to onset of epileptiform activity in all 
experimental groups during a 180­min­long recording 
period following penicillin injection are presented as 
Fig. 1. 
F i g. 1. Examples of ECoG activity before (A) and after (B–E) penicillin G injections in different experimental groups. 
Р и с. 1. Приклади ЕКоГ активності перед ін’єкцією пеніциліну G (А) та після такої ін’єкції (B–E) в чотирьох досліджених групах.
T a b l e 1. Values of the Latency, sec (Onset Time of the First Epileptic Phenomenon) in the Experimental Groups 
Т а б л и ц я 1. Середні значення латентного періоду першого епізоду епілептичної активності в експериментальних групах
Groups N Mean Median s.d. Minumum Maximum P­value
Male control 7 445.86 358.00 193.15 240.00 801.00
    0.013Male genistein 7 419.71 446.00 51.41 330.00 468.00
Female control 7 649.00 660.00a,b,c 150.17 480.00 903.00
Female genistein 7 456.85 480.00 71.61 300.00 510.00
n –  number of examined rats; s.d. – standard deviation; a – female control group compared with female genistein (P < 0.032); 
b – fe male control group compared with male control (P < 0.015). c  – female control group compared with male genistein (P < 0.002).
A
B
C
D
E
NEUROPHYSIOLOGY / НЕЙРОФИЗИОЛОГИЯ.—2016.—T. 48, № 6472
A. BAHADIR, S. DEMIR, H. ORALLAR, et al.
F i g. 2. Median latencies (sec) in the experimental groups. 
a) female control group compared with female genistein (P < 0.032). 
b) female control group compared with male control (P < 0.015). 
c) female control group compared with male genistein (P < 0.002).
Р и с. 2. Медіанні значення латентного періоду першого 
комплексу пік/хвиля в експериментальних групах.
T a b l e 2. Values of the Frequency of the Spike/Wave Complexes in the Experimental Groups vithin the Observation Period  
Т а б л и ц я 2. Частота комплексів пік/хвиля в експериментальних групах протягом періоду спостереження 
Time,
min
Male control Male genistein Female control Female genistein P value
Mean ± s.d. Median Mean ± s.d. Median Mean ± s.d. Median Mean ± s.d. Median
10 82.6 ± 106.9 26.0 35.9 ± 38.2 33.0 33.1 ± 43.9 31.0 67.7 ± 134.0 19.0 0.855
20 201.1 ± 170.6 174.0 202.3 ± 188.9 242.0 207.0 ± 177.3 207.0 163.3 ± 152.4 127.0 0.975
30 229.9 ± 140.8 177.0 196.7 ± 143.5 155.0 205.9 ± 121.0 278.0 222.9 ± 143.1 268.0 0.956
40 253.3 ± 150.2 271.0 239.9 ± 147.6 239.0 302.9 ± 86.7 304.0 340.9 ± 94.9 352.0 0.406
50 282.3 ± 113.1 236.0 270.3 ± 152.3 231.0 276.4 ± 102.8 269.0 378.3 ± 121.1 367.0 0.314
60 304.0 ± 102.2 248.0 264.9 ± 153.5 221.0 237.7 ± 66.1 258.0 362.3 ± 148.3 344.0 0.341
70 286.9 ± 77.5 286.0 295.6 ± 124.6 283.0 213.1 ± 72.0 216.0 335.0 ± 143.3 347.0 0.231
80 270.6 ± 42.7 279.0 294.3 ± 153.5 216.0 228.7 ± 78.4 255.0 323.3 ± 176.4 302.0 0.639
90 250.4 ± 42.8 256.0 287.1 ± 162.5 188.0 235.0 ± 86.4 240.0 295.3 ± 175.3 274.0 0.922
100 219.3 ± 91.2 228.0 217.7 ± 158.5 175.0 316.4 ± 126.3 266.0 244.1 ± 110.9 224.0 0.551
110 197.4 ± 90.1 210.0 238.9 ± 175.2 169.0 306.4 ± 149.2 291.0 228.7 ± 87.0 185.0 0.623
120 173.3 ± 89.9 178.0 194.7 ± 116.8 168.0 306.7 ± 161.7 261.0 197.9 ± 94.4 179.0 0.291
130 154.0 ± 74.2 168.0 183.9 ± 94.2 147.0 266.7 ± 147.9 257.0 167.6 ± 70.5 206.0 0.376
140 154.9 ± 94.7 170.0 252.1 ± 148.2 182.0 269.0 ± 140.6 240.0 150.1 ± 79.9 176.0 0.223
150 164.1 ± 97.0 183.0 245.6 ± 166.9 188.0 243.1 ± 142.6 188.0 159.6 ± 60.6 183.0 0.645
160 136.7 ± 71.2 151.0 230.6 ± 155.2 175.0 201.9 ± 115.1 159.0 150.4 ± 54.0 151.0 0.632
170 162.3 ± 93.8 167.0 226.9 ± 165.3 169.0 231.9 ± 136.2 193.0 153.3 ± 49.9 155.0 0.772
180 132.6 ± 72.6 146.0 145.7 ± 89.9 168.0 185.4 ± 118.4 155.0 135.4 ± 71.1 132.0 0.958
F o o t n o t e: all intergroup differences did not reach the level of significance within all time periods.
We was mentioned, we used a low dose of genistein 
(100 µg/kg) in both female and male treated groups 
(FC and MC) which was determined in the previous 
study [18]. There was significant difference (P = 
= 0.013) observed between the values of the median 
latency (sec) to the first epileptic event among the 
experimental (G) and control (C) groups. Additionally, 
the median latency value in the FC group was 
significantly longer than the median latency in the 
MC, MG, and FG groups (respectively, P = 0.002, 
0.015, and 0.032; Fig. 2, Table 1). In other words, 
genistein manifested a clear proconvulsant effect by 
lowering the threshold of onset of epileptic seizures. 
At the same time, shortening of the latency on the 
epileptic activity induced with penicillin was observed 
in the female group (FG) only.
At the same time, no significant differences were 
found regarding the median spike/wave frequency 
(min–1) and median amplitude (µV) values of the 
epileptiform activity all examined groups (both 
gender and genistein/control) within all time periods 
(P > 0.05). It should be, however, mentioned that 
the respective intergroup differences of all indices, 
confirming the conclusion on the proconvulsant effect 
of ginesteine (while not reaching the significance 
level), were quite clear (Figs. 3, 4; Tables 2, 3). 
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T a b l e 3. Values of the Spike/Wave Amplitudes (µV) in the Experimental Groups vithin the Observation Period
Т а б л и ц я 3. Значення амплітуд (мкВ) комплексів пік/хвиля в експериментальних групах протягом періоду спостереження 
Time
(min)
Male control Male genistein Female control Female genistein P value
Mean ± s.d. Median Mean ± s.d. Median Mean ± s.d. Median Mean ± s.d. Median
10 1346.1 ± 700.7 1406.0 1454.7 ± 743.4 1633.9 1290.0 ± 758.0 1604.1 1655.9 ± 660.8 2006.6 0.780
20 1653.9 ± 443.0 1854.8 1276.9 ± 590.2 1210.5 1632.3 ± 574.9 2048.0 1641.1 ± 285.5 1695.3 0.401
30 1357.8 ± 544.6 1298.2 1360.5 ± 483.4 1221.0 1433.9 ± 468.6 1470.4 1545.3 ± 380.5 1677.0 0.876
40 1374.8 ± 451.7 1588.5 1434.9 ± 475.6 1394.2 1807.8 ± 329.6 2043.3 1817.1 ± 246.5 1803.0 0.094
50 1518.5 ± 450.2 1355.9 1375.5 ± 350.7 1321.7 1745.0 ± 294.9 1633.2 1799.1 ± 264.0 1810.0 0.078
60 1588.4 ± 423.5 1488.0 1316.0 ± 265.3 1291.7 1732.7 ± 255.9 1597.0 1850.9 ± 240.0 2013.7 0.084
70 1549.5 ± 478.7 1407.6 1446.4 ± 368.9 1300.9 1688.6 ± 302.7 1641.3 1787.4 ± 275.1 1748.3 0.221
80 1552.5 ± 458.0 1508.7 1447.5 ± 427.2 1261.0 1801.0 ± 250.7 1744.5 1729.7 ± 326.2 1724.0 0.126
90 1519.0 ± 495.8 1613.8 1451.9 ± 454.2 1280.2 1683.8 ± 285.3 1677.7 1673.9 ± 392.7 1758.3 0.731
100 1470.3 ± 550.5 1731.3 1668.9 ± 499.1 2047.8 1761.8 ± 299.8 1790.8 1561.1 ± 281.9 1676.8 0.536
110 1425.2 ± 594.2 1738.0 1463.6 ± 596.8 1329.5 1696.1 ± 262.5 1625.8 1483.7 ± 274.6 1549.1 0.817
120 1403.9 ± 600.0 1745.4 1496.2 ± 547.4 1326.2 1667.7 ± 351.4 1806.6 1418.7 ± 258.9 1482.8 0.651
130 1298.7 ± 636.8 1549.4 1555.8 ± 474.8 1334.0 1625.0 ± 396.0 1788.7 1588.0 ± 425.6 1651.7 0.758
140 1334.1 ± 723.8 1738.0 1427.6 ± 449.3 1261.0 1646.4 ± 351.6 1677.7 1471.8 ± 475.2 1308.9 0.700
150 1330.4 ± 672.5 1745.4 1444.7 ± 467.4 1280.2 1610.3 ± 395.3 1592.5 1532.1 ± 504.9 1530.8 0.897
160 1458.8 ± 636.6 1588.6 1510.1 ± 531.2 1323.9 1557.1 ± 431.1 1614.9 1510.6 ± 478.7 1549.1 0.971
170 1493.5 ± 711.3 1794.2 1499.0 ± 552.7 1329.5 1558.6 ± 435.8 1611.7 1525.6 ± 454.4 1533.9 0.964
180 1346.1 ± 700.7 1406.0 1454.7 ± 743.4 1633.9 1290.0 ± 758.0 1604.1 1655.9 ± 660.8 2006.6 0.878
F o o t n o t e: all intergroup differences did not reach the level of significance within all time periods.
F i g. 3. Dynamics of the medians 
of the spike/wave frequency (min–1) 
in different experimental groups 
within the observation period. 
 Columns 1–4, male control, male 
genistein, female control, female 
genistein groups, respectively. 
Р и с. 3. Динаміка медіанних зна-
чень частоти комплексів пік/хви-
ля (хв–1) в експериментальних 
групах.
F i g. 4. Dynamics of the medians 
of the spike/wave amplitude (μV) 
in different experimental groups 
within the observation period. 
Designations are similar to those as 
in Fig. 3.
Р и с. 4. Динаміка медіанних зна-
чень амплітуди комплексів пік/
хвиля (мкВ) в експерименталь-
них групах.
min–1
123 4
min
μV
123 4
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DISCUSSION
Estrogens and phytoestrogens regulate the neuronal 
excitability by either their influence on the release of 
neurotransmitters from presynaptic terminals (such 
as acetylcholine, dopamine, GABA, and glycine) 
or direct effects on different ion channels in the 
postsynaptic membrane structures. Moreover, it has 
been reported that these hormones influence both the 
seizure threshold and frequency of epileptic activity [7, 
9]. Also, sex gonadal hormones have different effects 
according to sex­dependent differential influences on 
the severity of seizures in experimental rat models 
[10­12]. It has been indicated that phytoestrogens of 
the soy extract may mimic the estrogen proconvulsant 
effect in a PTZ­induced seizure model. Both low and 
high doses of soy extract treatment affected the seizure 
severity in the model, but their effects were different 
in the presence or absence of ovarian hormones [19]. 
Genistein, a relatively selective ER b­agonist, is an 
isoflavone phytoestrogenic molecule; its structure is 
rather similar to 17b­estradiol [20]. It exhibits PTK 
activity; this enzyme plays important roles in many 
cellular processes, as was shown in in vivo and in vitro 
studies [15, 16]. It was reported that genistein exerts 
neuroprotective effects against neurodegenerative 
diseases [21, 22]. In addition, genistein was described 
as an effective agent in both prophylaxis and treatment 
of hormone­dependent cancers, in particular, those 
of breast and endometrium [23]. Accordingly, many 
studies suggested that genistein may be used as an 
alternative to ERT; it reproduces the neuroprotective 
effect of estrogen without cancer­promoting adverse 
effects of the latter [24, 25]. However, the mechanisms 
of the effects of genistein on epileptic activity have 
not been finally determined until now.
Our study was performed to investigate the effects 
of genistein in penicillin­induced epilepsy model and 
to evaluate possible gender­dependent differences. 
To our knowledge, this is the first study to address 
changes of the epileptiform activity after genistein 
treatment to female and male rats in the above­
mentioned epilepsy model. 
Genistein penetrates the blood­brain barrier in a 
dose­dependent manner, and can be defined in the 
brain tissue. It’s concentration in this tissue was 
found to be lower than the levels observed in other 
tissues [26, 27]. In our study, genistein was given 
during 15 days to the female and male treated rat 
groups before cortical injections of penicillin G that 
induced epileptiform activity. We took into account 
that genistein shows a relatively low penetration rate 
through the blood­brain barrier. Thus, our results 
illustrate chronic effects of small doses of genistein 
in experimental epilepsy model.  Genistein can be 
dissolved in various solvents, such as DMSO, ethanol, 
propylene glycol, olive oil, or sesame oil, and this also 
can affect the obtained experimental results. 
We found that genistein facilitated the onset of 
epilepsy in female group (FG) of the rat model, and we 
used DMSO as solvent for genistein. Besides, Choi and 
Lee [18] demonstrated that chronic administration of 
high doses of genistein (20 mg/day) induced cytotoxic 
effects and apoptosis, while low doses of genistein 
(2 mg/day) had no cytotoxic effect in the rat cerebral 
tissue. Considering this, in the present study we used 
a rather low dose (100 µg/kg) of genistein showing no 
cytotoxic and apoptotic effects according [18]. 
In our study, we observed significant differences in 
the latency to onset of epileptiform activity among all 
female and male genistein/control groups. We found 
that low dose genistein treatment facilitated starting of 
epileptiform seizures but only in a female group (FG), 
while such treatment did not changed significantly 
the onset time of first epileptic manifestation in the 
male group (MG). In other words, the latency in the 
FG group was significantly shorter than that in both 
male groups (MC and MG) and female control group 
(FC). The proconvulsant effect of genistein arises 
from its estrogen­like activity, and these findings 
may be related to two possible mechanisms. Genistein 
may exert a negative regulatory effect on the GABA­
system activity [17]. Other mechanism may be the 
following; flavonoids like genistein partly inhibit 
acetylcholinestherase. Thus, it delays degradation of 
the respective neurotransmitter [28]. We think that the 
proconvulsant effect of genistein may result from both 
above reasons. 
Furthermore, in the present study, genistein 
treatment did not demonstrate significant differences 
with regard to the spike/wave frequency or amplitude 
values between both female and male rats, while the 
respective trends were noticeable. These results may 
arise from interaction of three different mechanisms. 
The first one may be based on inhibition of voltage­
gated sodium currents by genistein. This was shown 
in rat superior cervical ganglion (SCG) neurons 
and realized through PTK­dependent and kinase­
independent signal pathways [15]. Thus, genistein 
suppress the neuronal excitability by reducing 
the depolarization rate in neuronal units. The 
second mechanism may be due to changes in the 
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depolarization state of the cell by estrogen­induced 
blocking of Na+,K+­ATPase pump activity. It was 
reported that functioning of this pump is significantly 
increased under conditions of an estrogen deficiency 
in ovariectomized rats [29]. The third mechanism 
may arise from the formation of membrane 
hyperpolarization resulting from an increase in ATP­
dependent potassium channel (K
ATP
) activity related to 
estrogen effect in neuronal cells [30]. We believe that 
the absence of significant differences in the genistein 
effects on the frequency and amplitude ECoG values, 
observed in our studies, are determined by a combined 
nature of the nature of genistein effects and complex 
interactions between the factors of this treatment in 
both female and male groups. Further research is 
needed of explain the exact reason observed pattern 
of proconvulsant effects of genistein observed in our 
experiments. 
Our study, naturally, has a number of considerable 
limitations.  We did not study the dose­dependence 
of genistein treatments in non­cytotoxic doses and 
the influence of different solvents. Additionally, 
female rats were tested randomly for epileptic activity 
regardless of their ovulation cycle stage. Individual 
hormonal cycle stages may play a significant role 
in seizure susceptibility. One another disadvantage 
was that we had no data on the effects of genistein 
depending of the level of ovarian hormones. In 
further research, application of genistein under 
various estrogen conditions (females, i.e., standard 
estrogen condition, males, i.e., naturally low­estrogen 
condition, and ovariectomized rats, artificially induced 
estrogen deficiency) is expedient. We did not examine 
the relationship between the effects of genistein 
and hormone levels such as estradiol (E2), and 
progesterone (P4) contents, in the rat plasma, as well 
as interrelations of these indices with epileptiform 
activity.
In any case, we suggest that genistein, according to 
the results of our study,  may not be a good candidate 
in ERT, because it can noticeably increase the epileptic 
seizure susceptibility in female individuals.
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Р е з ю м е
Ми досліджували залежні від статі відмінності впливу ґе-
ністеїну (ізофлавоноїдного фітоестрогена) в умовах інду-
кованої пеніциліном експериментальної моделі епілепсії у 
щурів. 28 дорослих щурів лінії Вістар (14 самиць і 14 сам-
ців) були поділені на чотири групи – контрольних та ліко-
ваних ґеністеїном самців і самиць. Ґеністеїн (100 мкг/кг, 
внутрішньоочеревинно) або фізіологічний розчин уводив-
ся тваринам протягом 15 діб, після чого у них відводились 
електрокортикограма (ЕКоГ). Епілептиформна активність 
індукувалась ін’єкцією пеніциліну G калієвої солі (500 МО) 
в ліву соматомоторну кору. Істотні міжгрупові відмінності 
були виявлені щодо латентного періоду початку епілепти-
формної активності (P = 0.013). Ця величина в контрольній 
групі самиць була істотно більшою, ніж аналогічні значення 
в контрольній групі самців та групах самців і самиць, ліко-
ваних ґеністеїном (P = 0.002, 0.015 та 0.032 відповідно). Не 
було виявлено істотних відмінностей щодо частоти комп-
лексів пік/хвиля та амплітуди епілептиформної активності 
у всіх чотирьох груп у межах інтервалу спостережень (P > 
> 0.05). Зроблено висновок, що ґеністеїн впливає на пені-
цилініндуковану модель епілепсії як проконвульсант; відпо-
відні ефекти демонструють значну гендерну специфіку, оче-
видно, залежну від гормонального фону в самців і самиць. 
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